Jazz Pharmaceuticals Inc

Type: Company

Name: Jazz Pharmaceuticals Inc

Nationality: United States

Web Address: http://www.jazzpharmaceuticals.com

First reported 17 hours ago - Updated 17 hours ago - 1 reports

Cubist Pharmaceuticals Inc

NPS Pharma Prices Offering Zacks

NPS Pharmaceuticals, Inc. (NPSP) recently priced a public offering of 6,000,000 shares at $14.53 a share, with a 30-day over-allotment option for an additional 900,000 shares. NPS Pharma expects to raise approximately $87.2 million from the offering, ... [Published Yahoo! Finance - 17 hours ago]

Entities: NPS Pharmaceuticals Inc, GATTEX, Short Bowel Syndrome, Jazz Pharmaceuticals Inc, Cubist Pharmaceuticals Inc

First reported 17 hours ago - Updated 17 hours ago - 1 reports

Jazz Pharmaceuticals Inc

Form 4 Jazz Pharmaceuticals For: May 21 Filed by: COZADD BRUCE C

StreetInsider.com - Form 4 Jazz Pharmaceuticals For: May 21 Filed by: COZADD BRUCE C ... [Published Street Insider - 17 hours ago]

Entities: Jazz Pharmaceuticals Inc

First reported May 22 2013 - Updated 17 hours ago - 2 reports

ARM Holdings plc

Sector Leaders Reverse Higher, But Some Close Lower

Posted 06:01 PM ETThe Sector Leaders erased much of their morning losses, and some managed to close with gains Thursday.Jazz Pharmaceuticals (JAZZ) broke out of a cup with handle on Wednesday and closed Thursday still within a buy range.The stock reversed ... [Published Investors Business Daily - 17 hours ago]

Entities: ARM Holdings plc, Ocwen Financial Corp, Jazz Pharmaceuticals Inc

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Mylan Incorporated

The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz Pharmaceuticals

/PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ... [Published FinanzNachrichten.de - May 23 2013]

Entities: Mylan Incorporated, Zumiez Inc, ABBVIE INC., Jazz Pharmaceuticals Inc, Santarus Inc

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Form 4 Jazz Pharmaceuticals For: May 20 Filed by: Cox Russell J.

StreetInsider.com - Form 4 Jazz Pharmaceuticals For: May 20 Filed by: Cox Russell J. ... [Published Street Insider - May 23 2013]

Entities: Jazz Pharmaceuticals Inc

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Bristol-Myers Squibb Company

Bristol-Myers, Jazz Pharmaceuticals Lead Pharma Rally

Drugmakers of all stripes rocketed in early trade Wednesday, although many pared gains sharply before the end of the session. The Amex Pharmaceutical Index trimmed its initial 1.3% gain to less than 1%. Market Vector's Biotech ETF (BBH) erased a 3% gain ... [Published Investors Business Daily - May 22 2013]

Entities: Jazz Pharmaceuticals Inc, Bristol-Myers Squibb Company, fractionation, Citigroup Inc, Biotechnology

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Standard & Poor's

Jazz Pharmaceuticals Makes a Move: Up 3.5%

(Financial News Network On) Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of today's biggest movers, up 3.5% to $62.11. The Dow is up 0.5% to 15,462 and the S&P is currently up 0.4% to 1,676. Jazz Pharmaceuticals, Inc. develops and markets treatments f ... [Published Individual.com - May 22 2013]

Entities: Jazz Pharmaceuticals Inc, treatments, Standard & Poor's

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Jazz Pharmaceuticals (JAZZ) Has Climbed Past Resistance At The Highs

Jazz Pharmaceuticals (JAZZ: Quote) has been gaining ground since the open of trade Wednesday. The stock is currently higher by 3.44 at $63.44 on above average volume.Jazz Pharmaceuticals has broken out past resistance this morning and has set a new high ... [Published RTTNews.com - May 22 2013]

Entities: Jazz Pharmaceuticals Inc

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Jazz Pharmaceuticals (JAZZ) Trading Near $61.80 Resistance Level

Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ) closed Tuesday's trading session at $60.00. In the past year, the stock has hit a 52-week low of $40.38 and 52-week high of $60.79. Jazz Pharmaceuticals (JAZZ) stock has been showing support around $57.42 and resistance ... [Published MarketIntelligenceCenter.com - May 22 2013]

Entities: Jazz Pharmaceuticals Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Jazz Pharmaceuticals Public Limited Company Presents at UBS Global Healthcare Conference, May-21-2013 09:30 AM

Ami Fadia - UBS Investment Bank, Research DivisionGood morning, everybody. Thanks for coming to the UBS Conference. I'm Ami Fadia. I cover mid-cap spec pharma stocks at UBS. It's my pleasure to have Kate, who is the CFO of Jazz Pharmaceuticals, to present. ... [Published Seeking Alpha - May 21 2013]

Entities: asparaginase, Xyrem, PRIALT

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Jazz Pharmaceuticals reports higher Q1 net income, provides outlook for 2013

Jazz Pharmaceuticals plc, a specialty biopharmaceutical company, has reported that net income for the first quarter ended March 31, 2013 was $43.42 million, or $0.71 per diluted share, compared to $27.68 million, or $0.48 per diluted share, for the same ... [Published Individual.com - May 20 2013]

Entities: Jazz Pharmaceuticals Inc, Xyrem, Cash Position

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Jazz Pharmaceuticals Earnings In Retrospect: Down 1.9% in the Last 11 Days (JAZZ)

(Financial News Network On) 11 days ago, on May 7th, 2013, Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its earnings. Analysts, on average, expected earnings of $1.33 per share on sales of $191.2 million. Jazz Pharmaceuticals actually reported earnings ... [Published Individual.com - May 18 2013]

Entities: Jazz Pharmaceuticals Inc

Quotes

...the field for ideas about the best chance of success with the molecule, and it hopes to conduct a proof-of-concept clinical study later this year. "We're being deliberate to find the right dosing and right indication for this potent molecule" Mr. Renz says

Zalicus Awaiting Data On Potential New Pain Medication [Published Seeking Alpha - May 23 2013]

...strong top and bottom line growth fueled by growing sales of Xyrem and Erwinaze," said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals plc. "We have made substantial progress in the execution of our strategy to maximize the potential of our product portfolio while further strengthening our cash position, positioning us to pursue promising corporate development opportunities and share repurchases."

Jazz Pharmaceuticals reports higher Q1 net income, provides outlook for 2013 [Published Individual.com - May 20 2013]

"Playing the mini tour and having to go through qualifying school, once you get out here you say, 'Wow, this is really nice.' The fans are wonderful, red carpet treatment, the golf courses we play are awesome. This is a really a class act. The mini tour we play is good and it's improved tremendously since I first started playing, but it's still not being out here."

Nicole Jeray's best round of year has her in contention after first round of Mobile Bay LPGA Classic [Published Mississippi Press - May 16 2013]

"I am pleased to welcome Nandan as our COO," said Vikram Lamba, Chief Executive Officer, Zosano Pharma. "His operational and manufacturing experience and expertise - as well as his leadership experience - will be critical in preparing Zosano for our next stage of commercial-scale manufacturing as we drive our clinical programs towards the marketplace."

Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer [Published NewsBlaze - May 14 2013]

More Content

sort by: Date \| Relevance
NPS Pharma Prices Offering Zacks [Published Yahoo! Finance - 17 hours ago]
Form 4 Jazz Pharmaceuticals For: May 21 Filed b... [Published Street Insider - 17 hours ago]
Sector Leaders Reverse Higher, But Some Close L... [Published Investors Business Daily - 17 hours ago]
Repros to Conduct Phase IIb Trial Zacks [Published Yahoo! Finance - 19 hours ago]
Ironwood Pharma Prices Stock Offering Zacks [Published Yahoo! Finance - May 23 2013]
The Zacks Analyst Blog Highlights: Zumiez, Myla... [Published FinanzNachrichten.de - May 23 2013]
The Zacks Analyst Blog Highlights: Zumiez, Myla... [Published StockHouse USA - May 23 2013]
The Zacks Analyst Blog Highlights: Zumiez, Myla... [Published Financial Services - May 23 2013]
Zalicus Awaiting Data On Potential New Pain Med... [Published Seeking Alpha - May 23 2013]
Form 4 Jazz Pharmaceuticals For: May 20 Filed b... [Published Street Insider - May 23 2013]
Sector Leaders Come Under Attack But Jazz Break... [Published Investors Business Daily - May 22 2013]
Bristol-Myers, Jazz Pharmaceuticals Lead Pharma... [Published Investors Business Daily - May 22 2013]
XenoPort Resumes Horizant Supply Zacks [Published Yahoo! Finance - May 22 2013]
Swiss Issue for AMAG/Takeda's Rienso Zacks [Published Yahoo! Finance - May 22 2013]
Additional Patent for Acorda's Ampyra - Analyst... [Published Nasdaq - May 22 2013]
Additional Patent for Acorda's Ampyra Zacks [Published Yahoo! Finance - May 22 2013]
Jazz Pharmaceuticals Makes a Move: Up 3.5% [Published Individual.com - May 22 2013]
Jazz Pharmaceuticals (JAZZ) Has Climbed Past Re... [Published RTTNews.com - May 22 2013]
AbbVie Extends Galapagos Deal Zacks [Published Yahoo! Finance - May 22 2013]
Jazz Pharmaceuticals (JAZZ) Trading Near $61.80... [Published MarketIntelligenceCenter.com - May 22 2013]
Jazz Pharmaceuticals Public Limited Company Pre... [Published Seeking Alpha - May 21 2013]
Elan Provides Strategic Update [Published Yahoo! Finance - May 21 2013]
Now Available: Jazz Pharmaceuticals plc (JAZZ) ... [Published Live-PR.com - May 21 2013]
FDA Accepts Actavis NDA Zacks [Published Yahoo! Finance - May 20 2013]
Jazz Pharmaceuticals reports higher Q1 net inco... [Published Individual.com - May 20 2013]
Tackling Cancer: Leukemia's Biggest Current and... [Published Motley Fool Discussion Boards - May 19 2013]
Jazz Pharmaceuticals Earnings In Retrospect: Do... [Published Individual.com - May 18 2013]
Jazz Pharmaceuticals plc (JAZZ) - Pharmaceutica... [Published TransWorldNews - May 17 2013]
Nicole Jeray's best round of year has her in co... [Published Mississippi Press - May 16 2013]
3 Value Investing Plays in Health Care [Published Motley Fool Discussion Boards - May 16 2013]

Blogs

sort by: Date \| Relevance
Jazz Pharmaceuticals (JAZZ) Trading Near $61.80... [Published MarketIntelligenceCenter.com - May 22 2013] Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ) closed Tuesday's trading session at $60.00. In the past year, the stock has hit a 52-week low of $40.38 and 52-week high of $60.79. Jazz Pharmaceuticals (JAZZ) stock has been showing support around $57.42 and resistance ...
Potential Jazz Pharmaceuticals (JAZZ) Trade Tar... [Published MarketIntelligenceCenter.com - May 15 2013] Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ) closed Tuesday's trading session at $59.00. In the past year, the stock has hit a 52-week low of $40.38 and 52-week high of $60.79. Jazz Pharmaceuticals (JAZZ) stock has been showing support around $57.85 and resistance ...
These 5 Stocks Saw Trading Price Swings This Pa... [Published Wall St. Cheat Sheet - May 12 2013] Cross Country Healthcare, Inc. ( NASDAQ:CCRN ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. Adjusted Earnings Per Share decreased to $-0.01 in the quarter versus EPS of $0.00 in the year-earlier ...
Deals of the Week: With Option Deal, Forest Kee... [Published The IN VIVO Blog - May 10 2013] It’s an optimistic time for pharma dealmakers, with the Dow and the Nasdaq Biotechnology Index climbing, buyers sitting on big piles of cash, and the IPO window as wide-open as it’s been in years. But for smaller companies that have long lamented that ...
Potential Jazz Pharmaceuticals (JAZZ) Trade Has... [Published MarketIntelligenceCenter.com - May 09 2013] Jazz Pharmaceuticals Inc. (NASDAQ: JAZZ) closed Wednesday's trading session at $55.25. In the past year, the stock has hit a 52-week low of $40.38 and 52-week high of $60.79. Jazz Pharmaceuticals (JAZZ) stock has been showing support around $52.20 and ...

Press Releases

sort by: Date \| Relevance
The Zacks Analyst Blog Highlights: Zumiez, Myla... [Published Financial Services - May 23 2013]
Jazz Pharmaceuticals Announces Participation In... [Published Financial Services - May 14 2013]
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 20... [Published PR Newswire: Financial Services - May 07 2013]
Jazz Pharmaceuticals To Report First Quarter 20... [Published PR Newswire: Health - Apr 23 2013]
Jazz Pharmaceuticals Announces Pricing Of Publi... [Published PR Newswire: Health - Mar 05 2013]